Diagnostic approach to chronic bowel diseases in children

Authors

DOI:

https://doi.org/10.15587/2519-4798.2022.265388

Keywords:

calprotectin, ulcerative colitis, non-ulcerative colitis, rritable bowel syndrome, diagnostics, children

Abstract

Diagnosing inflammatory bowel diseases in children and differentiating them from functional disorders is complicated based on clinical assessment, laboratory data, and radiological, endoscopic, and histological signs. Therefore, in paediatrics, substantial attention has been given to standard invasive evaluation methods. Recently, research efforts have been directed towards using faecal calprotectin as a sensitive non-invasive stool test.

The aim of the research was to study the diagnostic value of faecal calprotectin in pediatric chronic inflammatory bowel diseases. The paper discusses faecal calprotectin's diagnostic and monitoring role in 35 children aged 3 to 17 years with ulcerative colitis, non-specific non-ulcerative colitis, and irritable bowel syndrome. The concentration of the faecal calprotectin level was examined by ELISA using monoclonal antibodies.

Results. The study shows that in patients with non-specific ulcerative and non-ulcerative colitis, the faecal calprotectin level exceeds the normal ranges 2-5 times, corresponding to clinical and morphological manifestations of the diseases and the level of inflammatory markers. However, this biological marker does not exceed the average values in children with irritable bowel syndrome.

Conclusions. The faecal calprotectin test allows us to differentiate organic and functional intestinal diseases, monitor chronic inflammatory bowel disease activity dynamics, and estimate treatment effectiveness. Applying the faecal calprotectin test within the framework of primary medical care can decrease the number of referrals for invasive endoscopic, laboratory, and radiologic examinations in pediatric patients with inflammatory bowel diseases

Author Biographies

Tetiana Yaroshevska, Dnipro State Medical University

PhD, Associate Professor

Department of Propaedeutic of Children Diseases

Kateryna Skriabina, Dnipro State Medical University

Assistant

Department of Propaedeutic of Children Diseases

References

  1. Tontini, G. E., Vecchi, M., Pastorelli, L., Neurath, M. F., Neumann, H. (2015). Differential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectives. World Journal of Gastroenterology, 21 (1), 21–46. doi: https://doi.org/10.3748/wjg.v21.i1.21
  2. Misra, R., Faiz, O., Munkholm, P., Burisch, J., Arebi, N. (2018). Epidemiology of inflammatory bowel disease in racial and ethnic migrant groups. World Journal of Gastroenterology, 24 (3), 424–437. doi: https://doi.org/10.3748/wjg.v24.i3.424
  3. Stepanov, Yu. M., Skyrda, I. Yu., Petishko, O. P. (2017). Chronic inflammatory bowel diseases: epidemiological features in Ukraine. Gastroenterology, 51 (2), 97–105. doi: https://doi.org/10.22141/2308-2097.51.2.2017.101703
  4. Denisova, M. F., Muzyka, N. M., Cherneha, N. V., Zadorozhna, T. D., Archakova, T. M., Bukulova, N. Yu. (2017). Peculiarities of the course of ulcerative colitis in children at the present stage. Child’s Health, 12 (2), 136–141. doi: https://doi.org/10.22141/2224-0551.12.2.2017.99769
  5. Belousova, O. Yu. (2013). Chronic non-specific nonulcer colitis in children. Perinatologija i pediatrija, 1, 87–91. Available at: http://nbuv.gov.ua/UJRN/perynatology_2013_1_19
  6. Campbell, J. P., Zierold, C., Rode, A. M., Blocki, F. A., Vaughn, B. P. (2020). Clinical Performance of a Novel LIAISON Fecal Calprotectin Assay for Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome. Journal of Clinical Gastroenterology, 55 (3), 239–243. doi: https://doi.org/10.1097/mcg.0000000000001359
  7. Kawashima, K., Ishihara, S., Yuki, T., Fukuba, N., Oshima, N., Kazumori, H. et. al. (2016). Fecal calprotectin level correlated with both endoscopic severity and disease extent in ulcerative colitis. BMC Gastroenterology, 16 (1), 47–54. doi: https://doi.org/10.1186/s12876-016-0462-z
  8. Laserna-Mendieta, E. J., Lucendo, A. J. (2019). Faecal calprotectin in inflammatory bowel diseases: a review focused on meta-analyses and routine usage limitations. Clinical Chemistry and Laboratory Medicine (CCLM), 57 (9), 1295–1307. doi: https://doi.org/10.1515/cclm-2018-1063
  9. Haisma, S.-M., Verkade, H. J., Scheenstra, R., van der Doef, H. P. J., Bodewes, F. A. J. A., van Rheenen, P. F. (2019). Time-to-reach Target Calprotectin Level in Newly Diagnosed Patients With Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology & Nutrition, 69 (4), 466–473. doi: https://doi.org/10.1097/mpg.0000000000002458
  10. Fagerhol, M. K., Dale, I., Anderson, T. (2009). Release and Quantitation of a Leucocyte Derived Protein (L1). Scandinavian Journal of Haematology, 24 (5), 393–398. doi: http://doi.org/10.1111/j.1600-0609.1980.tb02754.x
  11. Khaki-Khatibi, F., Qujeq, D., Kashifard, M., Moein, S., Maniati, M., Vaghari-Tabari, M. (2020). Calprotectin in inflammatory bowel disease. Clinica Chimica Acta, 510, 556–565. doi: https://doi.org/10.1016/j.cca.2020.08.025
  12. Golovanova I. A., Bjelikova I. V., Ljahova N. O. (2017). The basics of medical statistics: a textbook for graduate students and clinical residents. Poltava, 113.

Downloads

Published

2022-09-30

How to Cite

Yaroshevska, T., & Skriabina, K. (2022). Diagnostic approach to chronic bowel diseases in children. ScienceRise: Medical Science, (5 (50), 52–56. https://doi.org/10.15587/2519-4798.2022.265388

Issue

Section

Medical Science